AMP
55
6
FDX
71
3
BRK.B
33
-3
MET
44
3
MCO
68
3
RHI
44
2
MAT
64
-4
GS
70
-2
APA
63
4
DGX
48
5
CL
50
3
PRU
62
3
CLX
59
3
XRAY
38
6
EFX
41
5
OMC
50
7
TXN
50
5
PEP
41
6
ORLY
52
2
ADT
61
6
AMP
55
6
FDX
71
3
BRK.B
33
-3
MET
44
3
MCO
68
3
RHI
44
2
MAT
64
-4
GS
70
-2
APA
63
4
DGX
48
5
CL
50
3
PRU
62
3
CLX
59
3
XRAY
38
6
EFX
41
5
OMC
50
7
TXN
50
5
PEP
41
6
ORLY
52
2
ADT
61
6
Financhill
Back

Theravance Biopharma, Inc. Stock Predictions

Exxon and Chevron Have an Unlikely New Competitor

DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at
Buy
62

TBPH
Theravance Biopharma, Inc.

Last Price:
$20.11
Seasonality Move:
0.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Meet America's Newest $1B Unicorn

DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at

Theravance Biopharma, Inc. Stock Forecast

  • Over the next 52 weeks, Theravance Biopharma, Inc. has on average historically risen by 9.7% based on the past 11 years of stock performance.
  • Theravance Biopharma, Inc. has risen higher in 3 of those 11 years over the subsequent 52-week period, corresponding to a historical accuracy of 27.27%
  • Is Theravance Biopharma, Inc. Stock Undervalued?
    The current Theravance Biopharma, Inc. [TBPH] share price is $20.61. The Score for TBPH is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.
  • TBPH is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.

Will Theravance Biopharma, Inc. Stock Go Up Next Year?

  • Over the next 52 weeks, Theravance Biopharma, Inc. has on average historically risen by 9.7% based on the past 11 years of stock performance.

Theravance Biopharma, Inc. Stock Rating

Buy
62
Theravance Biopharma, Inc. (TBPH) is a Buy

Is Theravance Biopharma, Inc. overpriced?

  • Theravance Biopharma, Inc. has risen higher in 3 of those 11 years over the subsequent 52-week period, corresponding to a historical accuracy of 27.27%

Theravance Biopharma, Inc. Stock Price History

Is TBPH stock going to rise?

  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and TBPH is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Pharmaceuticals
Sector:
Health Care
Type:
stock
Website:
theravance.com

52-Week Data

52-Week High:
20.69
52-Week Low:
7.90

Prediction Charts

Market Cap:
1B
Price in USD:
20.61
Volume:
306.9K
Beta:
0.73

Technical Analysis

SMA50:
18.14
SMA100:
16.12
SMA200:
13.27
52-Wk Change:
141.62%

Stock Predictions

  • Is Theravance Biopharma, Inc. stock public?
    Yes, Theravance Biopharma, Inc. is a publicly traded company.
  • What is the Theravance Biopharma, Inc. stock quote today?
    The Theravance Biopharma, Inc. stock price is 20.61 USD today.
  • How to buy Theravance Biopharma, Inc. stock online?
    You can buy Theravance Biopharma, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Dec-24 18.72 18.73 18.81 18.50
Dec-26 18.75 18.84 18.97 18.55
Dec-29 18.73 18.71 18.74 18.51
Dec-30 18.69 18.91 19.03 18.69
Dec-31 18.91 18.71 19.22 18.69
Jan-2 18.68 18.15 18.74 18.00
Jan-5 18.01 18.42 18.46 17.59
Jan-6 18.34 18.30 18.69 18.05
Jan-7 18.41 18.88 19.25 18.31
Jan-8 18.71 19.02 19.06 18.53
Jan-9 19.02 19.04 19.28 18.89
Jan-12 19.02 19.65 19.79 18.41
Jan-13 19.63 20.33 20.44 19.17
Jan-14 20.24 20.61 20.69 20.03

Theravance Biopharma, Inc. Earnings

Theravance Biopharma, Inc. Earnings Report: Per Share Theravance Biopharma, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Theravance Biopharma, Inc. Forecast Revenue Growth

Theravance Biopharma, Inc. Stock Analysis: Historical quarterly revenues per share for Theravance Biopharma, Inc. and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.03 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.18 per share, and an increase next year of $0.26 per share.

* Theravance Biopharma, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.